Natera, Inc., a diagnostics company, provides molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born. The company also provides Signatera molecular residual disease test for assessment and surveillance of disease recurrence in patients previously diagnosed with cancer; Altera, a tissue based genomic profiling test, that provides insight into genomic alterations and biomarkers; Prospera to assess active rejection in patients who have undergone kidney, heart, and lung transplantation; and Renasight, a kidney gene panel test. In addition, it offers Constellation, a cloud-based software product. It serves independent laboratories, national and regional reference laboratories, medical centers and physician practices, research laboratories, and pharmaceutical companies through its direct sales force, and a network of laboratory and distribution partners. It has a partnership agreement with BGI Genomics Co., Ltd. to develop, manufacture, and commercialize NGS-based genetic testing assays; and Foundation Medicine, Inc. to develop and commercialize personalized circulating tumor DNA monitoring assays. The company was formerly known as Gene Security Network, LLC and changed its name to Natera, Inc. in January 2012. Natera, Inc. was founded in 2003 and is headquartered in Austin, Texas.

Natera, Inc.

An update from IC Enterra Yenilenebilir Enerji AS ( ($TR:ENTRA) ) is now available. IC Enterra Yenilenebilir Enerji AS has released its summary con...

IC Enterra Publishes Audited Interim Financials for First Half of 2026

IC Enterra Yenilenebilir Enerji AS ( ($TR:ENTRA) ) has provided an update. IC Enterra Yenilenebilir Enerji A.S. has issued a consolidated represent...

IC Enterra board affirms accuracy of H1 2026 financial reporting

IC Enterra Yenilenebilir Enerji AS ( ($TR:ENTRA) ) has issued an announcement. IC Enterra Yenilenebilir Enerji A.S. has released its consolidated o...

IC Enterra details H1 2026 operations, governance and executive pay

In a report released today, Patrick B Donnelly from Citi maintained a Buy rating on Natera, with a price target of $365.00. According to TipRanks, ...

Natera (NTRA) Gets a Buy from Citi

Stephens analyst maintained a Buy rating on Natera today and set a price target of $350.00. In addition to Stephens, Natera also received a Buy fro...

Stephens Keeps Their Buy Rating on Natera (NTRA)

Piper Sandler analyst David Westenberg maintained a Buy rating on Natera today and set a price target of $249.00. Westenberg covers the Healthcare ...

Piper Sandler Sticks to Its Buy Rating for Natera (NTRA)

In a report released today, Casey Woodring from J.P. Morgan reiterated a Buy rating on Natera, with a price target of $360.00. According to TipRank...

J.P. Morgan Sticks to Their Buy Rating for Natera (NTRA)

Natera Inc. ($NTRA) announced an update on their ongoing clinical study. The SCORE-NHL study, officially titled “Sample Collection for Ongoing Rese...

Natera’s SCORE-NHL Study Builds Long-Term Value in Lymphoma Monitoring

IC Enterra Yenilenebilir Enerji AS ( ($TR:ENTRA) ) has provided an announcement. IC Enterra Yenilenebilir Enerji AS has advanced its 485 MW storage...

	A	B	C	D
1	Symbol	Price	Change	Volume
2	NTRA	$324.74	-0.13%	359.86K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	NTRA	$324.74	-0.1%	359.86K
3
4
5
6

NTRA

Get Natera, Inc. Data in Excel

Get Natera, Inc. Data in Excel